Photocure ASA said its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration (NMPA) has accepted its new drug application or NDA for the regulatory review of Cevira (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China.
Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com